Astrazeneca Ab

Mikael Thune

Anders Magnusson

Per Johan Lundberg

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein Rrepresents Calkyl substituted by one or more fluoro substituents; Rrepresents hydrogen, hydroxy, methoxy or ethoxy, and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier; provided that the formulation may only contain iota-carageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder. 

Modified release pharmaceutical formulation

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein Rrepresents C?1-2#191 alkyl substituted by one or more fluoro substituents; Rrepresents hydrogen, hydroxy, methoxy or ethoxy; and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier, provided that the formulation may only contain iota-carrageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder 

The present invention is related to an effervescent pharmaceutical preparation comprising effervescent excipients and a plurality of individual units comprising a pharmaceutically active compound and optional excipients wherein the units (,) are provided with a floating generating system. The floating generating systems comprises at least two coating layers, one of which is a gas generating layer (,) and the other layer is a barrier layer (,) enclosing the generated gas. Furthermore the invention is related to a process for the manufacture of the dosage forms, and their use in medicine.

Growing community of inventors

Mölndal, Sweden

Mikael Thune